Cytokines News and Research

Latest Cytokines News and Research

Rheumatoid arthritis may increase risk of dying from COVID-19

Researchers in New Zealand and Australia have conducted a study showing that people with rheumatoid arthritis may be at an increased risk of death if they develop coronavirus disease 2019 (COVID-19) after becoming infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

11 Nov 2020

Microbes in the lungs could influence lung cancer progression and prognosis

Bottom Line: Enrichment of the lungs with oral commensal microbes was associated with advanced stage disease, worse prognosis, and tumor progression in patients with lung cancer.

11 Nov 2020

How SARS-CoV-2 blocks immune response

An international research team has confirmed the mechanism by which the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). Their article titled, “SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling,” is published in the journal Proceedings of the National Academy of Sciences.

11 Nov 2020

Novel super-activating macrophage receptor could explain hyper-inflammation in severe COVID-19

Immunity is a curious thing. While essential in protecting the body against invading pathogens and foreign antigens, it can also turn against the body and trigger destructive immunological processes. A new study published on the preprint server bioRxiv* in November 2020 reports on the role played by hyperactive macrophages in a range of acute and chronic hyper-inflammatory conditions.

10 Nov 2020

Endothelial cells resistant to SARS-CoV-2 infection

A team of scientists from Imperial College London has conducted a series of in vitro studies to investigate the susceptibility of endothelial cells to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the causative pathogen of coronavirus disease 2019 (COVID-19).

10 Nov 2020

Promising yeast-expressed SARS-CoV-2 vaccine candidate effective in mice

Researchers at the Texas Children's Hospital Center for Vaccine Development, USA, have published a report on the preprint server bioRxiv that describes a yeast-expressed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor-binding domain (RBD) protein, a key target of current vaccine development efforts.

9 Nov 2020

Translational study within SARS-CoV-2 infected cells opens up new therapeutic avenues

A recent study published on the preprint server bioRxiv in October 2020 shows what the protein translation process looks like in specific terms. In doing so, the study has provided new insights that might prove helpful in developing new therapies for COVID-19 patients.

9 Nov 2020

Rapid rise in CRP levels predicts COVID-19 outcomes

Predicting the course of a COVID-19 patient's disease after hospital admission is essential to improving treatment.

6 Nov 2020

SARS-CoV-2 T-cell immunity is retained for at least six months

Now, a new study published on the preprint server bioRxiv shows that functional SARS-CoV-2-specific T-cell responses are retained for six months following infection. However, the strength of this response depends on the clinical features of the primary infection.

3 Nov 2020

Some of the main osteoporosis treatments could have a protective effect against COVID-19

Some of the principal treatments for osteoporosis, denosumab, zoledronate and calcium, could have a protective effect against COVID-19 in patients who take them, specifically a 30 to 40% reduction in the rate of infection, according to the results of a joint study by Hospital del Mar, the Hospital del Mar Medical Research Institute (IMIM), Pompeu Fabra University and the Pere Virgili Health Park.

3 Nov 2020

SARS-CoV-2 viroporin triggers NLRP3 inflammasome causing a severe inflammatory response

Now, a team of researchers at the University of Florida report that the SARS-CoV-2 viroporin triggers the NLR Family Pyrin Domain Containing 3 (NLRP3) inflammasome, which is responsible for the inflammatory pathology in severely ill COVID-19 patients.

30 Oct 2020

New therapeutic approach brings hope for treating psoriasis

Disruptive innovations in psoriasis are leading the way at EADV's 29th Congress, EADV Virtual. New data published today shows the first clinical evidence of modulating systemic inflammation by oral delivery of a non-living single strain commensal microbe.

29 Oct 2020

Research shows why certain people infected with COVID-19 show no symptoms

Researchers worldwide have been surprised to see that individuals can be infected with the SARS-CoV-2 virus - the virus that produces COVID-19 - without showing symptoms. Since these individuals expose others to infection without knowing it, it is important to find an explanation and hopefully a solution to this.

29 Oct 2020

DNase coated melanin-like nanospheres for sepsis treatment in severe COVID

As the treatment of severe COVID-19 is very difficult, the researchers from the Korea Research Institute of Biosciences and Biotechnology (KRIBB) suggested that DNase-1 can be utilized to dissolve the neutrophil extracellular traps (NETs), hence halting the further progression of COVID-19.

27 Oct 2020

Lung biomarkers may predict severe COVID-19

Two University of New Mexico researchers postulate certain specific biomarkers' relevance in predicting the potential for progression to severe COVID-19 in a paper published on the preprint server bioRxiv*

27 Oct 2020

Cellular senescence variations may control health and onset of age-related diseases

Researchers from Kumamoto University, Japan have proposed that cellular senescence variations during the aging process could lead to control of health and onset of age-related diseases.

27 Oct 2020

Anti-inflammatory mediator may play key role in wound healing

"Wound healing is one of the most complex biological processes," writes Professor Kazumitsu Sugiura and Dr. Kenta Saito from Fujita Health University, Japan, in their article recently published in Nature's Scientific Reports.

27 Oct 2020

New research on small non-coding RNAs and SARS-CoV-2

A recently published mini-review in the Frontiers in Microbiology on the altered expression of small non-coding RNAs during coronavirus-mediated infections.

26 Oct 2020

Tocilizumab fails to affect COVID-19 disease outcomes in Boston trial

Researchers from the various Massachusetts hospitals performed the Boston Area COVID-19 Consortium (BACC) Bay Tocilizumab Trial using tocilizumab administered early in the disease course to determine if early IL-6 receptor blockade limits progression of COVID-19 to hypoxemic respiratory failure or death. Their work is published in the prestigious New England Journal of Medicine.

25 Oct 2020

New therapeutic approach for treating patients with compromised immune systems

A young woman who had been hospitalized for three months straight due to debilitating, recurrent infections with no apparent underlying cause was finally able to go home thanks to a Massachusetts General Hospital (MGH) team who put their heads together, discovered a root of the problem, and developed a novel treatment strategy just for her.

23 Oct 2020